Immunogenicity of N-[-4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer

Five transplantable TCC initially induced by the carcinogen FANFT were systematically tested for individual immunogenicity and then for the presence of cross-reacting tumor antigens. The classic amputation challenge technique was used. Three of the 5 tumors were immunogenic, as determined by their ability to reduce the growth of a challenge tumor dose in mice immunized with the same bladder tumor. Prior immunization with one of the immunogenic tumors failed to reduce the incidence or growth of primary bladder tumors induced by the ingestion of 0.1% FANFT in C3H/HeJ mice. The lack of cross-reacting tumor antigens had important implications for the use of allogeneic tumor cells as an antigen source in immunotherapy.